The immune system and response to HER2-targeted treatment in breast cancer
- 1 February 2014
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (2), e58-e68
- https://doi.org/10.1016/s1470-2045(13)70477-7
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (AIRC) (MFGA 13428)
This publication has 90 references indexed in Scilit:
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled AnalysisJournal of Clinical Oncology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatmentCancer Immunology, Immunotherapy, 2011
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunityImmunologic Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancerEuropean Journal of Cancer, 2010
- Oncogenic stress sensed by the immune system: role of natural killer cell receptorsNature Reviews Immunology, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008